Abstract:Alternative precursor messenger RNA (pre-mRNA) splicing plays an important role in the generation of functional diversity of the genome. The process of pre-mRNA splicing is regulated by cis- and trans-elements, and their deregulations result in aberrantly spliced individual variants and aberrant expression profiles. Accumulating evidence has revealed that aberrant splicing contributes to a number of diseases including human neoplasms. It is well known that germ line mutations in the cis-element of tumor suppressor genes such as mismatch repair (MMR) genes, the adenomatous polyposis coli (APC) gene and the E-cadherin (CDH1) gene are involved in Lynch syndrome, familial adenomatous polyposis and hereditary diffuse gastric cancer, respectively. In addition, somatic mutations in cis-elements also play a role in tumorigenesis. These genetic alterations including nonsense, missense or silent mutations in cis-elements led to aberrant transcripts by exon skipping, retention of the intron or introduction of a new splice site. The majority of erroneous transcripts with a premature termination codon are eliminated through nonsense-mediated mRNA decay. However, it is difficult to accurately predict the resulting transcripts with current in silico strategies. Correct interpretation of genetic alterations and the investigation of aberrant transcripts are crucial for genetic diagnosis of hereditary diseases and elucidation of the molecular characteristics of neoplasms from a clinical point of view. In this review we summarize the current knowledge of the regulatory mechanism underlying alternative pre-mRNA splicing and aberrant splicing, with particular focus on digestive tract malignancies.

Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged.

Alternative splicing and cancer: a systematic review

[Disturbances of alternative splicing in cancer].

The role of alternative splicing in human cancer progression.

The role of alternative pre-mRNA splicing in cancer progression

Significance of Alternative Splicing in Cancer Cells.

Roles and mechanisms of alternative splicing in cancer — implications for care

Impacts and mechanisms of alternative mRNA splicing in cancer metabolism, immune response, and therapeutics

Mechanisms of Alternative Splicing Regulation: Insights from Molecular and Genomics Approaches

Regulation of RNA Splicing: Aberrant Splicing Regulation and Therapeutic Targets in Cancer

Alternative mRNA splicing in cancer immunotherapy

The implications of alternative pre-mRNA splicing in cell signal transduction

Dysregulation and therapeutic targeting of RNA splicing in cancer

RNA splicing dysregulation and the hallmarks of cancer

Aberrant Alternative Splicing in Breast Cancer

Aberrant RNA splicing in cancer; expression changes and driver mutations of splicing factor genes

Alternative Splicing As a Biomarker and Potential Target for Drug Discovery

Alternative pre-mRNA splicing in digestive tract malignancy

Aberrant Regulation of Alternative Pre-Mrna Splicing in Hepatocellular Carcinoma.

Alternative pre-mRNA splicing in stem cell function and therapeutic potential: A critical review of current evidence

Alternative Splicing in Myeloid Malignancies